-
Mashup Score: 5Durvalumab Plus Trastuzumab/Pertuzumab Elicits Responses in HER2-Enriched Breast Cancer - 25 day(s) ago
Dual HER2-targeted therapy plus checkpoint blockade may offer an effective, tolerable chemotherapy alternative in HER2-positive early breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Durvalumab Plus Trastuzumab/Pertuzumab Elicits Responses in HER2-Enriched Breast Cancer - 27 day(s) ago
Dual HER2-targeted therapy plus checkpoint blockade may offer an effective, tolerable chemotherapy alternative in HER2-positive early breast cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Saruparib Appears Safe, Active in Advanced Breast Cancer - 1 month(s) ago
Saruparib may be safe and effective for patients with homologous recombination repair-deficient, HER2-negative breast cancer.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Chemo-Free Regimen Appears Effective for HER2-Enriched Breast Cancer - 1 month(s) ago
A chemotherapy-free neoadjuvant treatment regimen can produce pathologic responses in patients with HER2-enriched early breast cancer.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
Administration of trastuzumab plus pertuzumab and durvalumab was tolerable and produced high pCRs comparable to those achieved with a standard salvage chemotherapy regimen in patients with HER2-enriched early breast cancer. @AACR #AACR24 #bcsm https://t.co/0Gsxr6P73s https://t.co/cXTqjZdDdp